- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
CPhI Worldwide Announces Finalists of Largest Ever Pharma Awards
CPhI Worldwide, organized by UBM (part of Informa PLC), has announced the finalists of the eagerly anticipated 2018 CPhI Pharma Awards.
This year’s edition features a record breaking number of entries, with over 250 from 174 participating companies across 17 categories, commending the innovations, technologies, and strategies driving pharma forward.
Such was the high caliber of entrants, 139 have been shortlisted, with the winners due to be announced during a live awards ceremony taking place at the luxurious Eurostars Madrid Tower Hotel on Tuesday October 9 – the opening day of CPhI Worldwide.
Innovations across flow chemistry, single-use technologies, drug delivery devices, contract services and packaging were amongst many shortlisted, with the judges concluding this was by far the highest ever standard of entries – further cementing 2018 as the year of innovation in pharma.
The awards for “Pharma company of the year”and “CEO of the year” will again be keenly sought as over 45,000 senior executives and 2500 companies attend at this year’s CPhI Worldwide.
To see the complete list of finalists, please visit https://awards.cphi.com/finalists/. The awards will be presented at the CPhI Awards Gala with over 350 guests in attendance.
To reserve a table for the CPhI Pharma Awards Gala, please visit https://awards.cphi.com/attend-the-gala/.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
